Last reviewed · How we verify
MENOPUR; GONAL-F
MENOPUR and GONAL-F are gonadotropins that stimulate the ovaries to produce multiple eggs for assisted reproductive procedures.
MENOPUR and GONAL-F are gonadotropins that stimulate the ovaries to produce multiple eggs for assisted reproductive procedures. Used for Infertility treatment via assisted reproductive technology (ART) / in vitro fertilization (IVF), Ovulation induction in anovulatory women.
At a glance
| Generic name | MENOPUR; GONAL-F |
|---|---|
| Sponsor | Central Jutland Regional Hospital |
| Drug class | Gonadotropin |
| Target | FSH receptor (FSHR); LH receptor (LHCGR) for MENOPUR |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | FDA-approved |
Mechanism of action
MENOPUR is a combination of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) derived from human menopausal urine, while GONAL-F is recombinant FSH. Both work by binding to FSH receptors on ovarian follicles to promote follicular growth and maturation, increasing estrogen production and preparing multiple oocytes for retrieval during in vitro fertilization or other fertility treatments.
Approved indications
- Ovulation induction and controlled ovarian hyperstimulation in assisted reproductive technology (ART) cycles
- Treatment of infertility in women with anovulation or poor ovarian response
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Headache
- Injection site reactions
- Abdominal pain/bloating
- Nausea
- Ovarian cysts
Key clinical trials
- A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (PHASE3)
- Comparison of Follitropin Delta and Follitropin Alfa in Combination With Menotropin
- Ovarian Hyperstimulation and Fibrin Clot Properties. (NA)
- Does Recombinant FSH (rFSH, i.g. Gonal F®) as Compared to Human Menopausal Gonadotrophin (hMG) Affect Telomere Length of Cumulus Cells During Antral Follicle Growth and Impact Blastocyst Status?
- Continuous Double Ovarian Stimulation. (PHASE4)
- Trigger Protocol on the Rate of Pregnancy After Intracytoplasmic Sperm Injection
- Hormone Evaluation in Artificial Reproductive Technology (NA)
- Impact of IVF Hormonal Therapy on Endometrial Receptivity and Endometrial Senescent Cell Pathological Accumulation
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MENOPUR; GONAL-F CI brief — competitive landscape report
- MENOPUR; GONAL-F updates RSS · CI watch RSS
- Central Jutland Regional Hospital portfolio CI